Project Grant R61HL175690
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$500K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...
This $317,001 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) will support the University of Texas at Austin's investigation of clot mechanics in pulmonary failure and thromboembolic disease in sickle cell anemia. The research aims to improve understanding and treatment of these conditions, which are of high relevance to military medicine. The 2-year project will leverage the university's...
This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...
This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the continued clinical development of a novel pleural and tracheal sealant. The $381,000 award to the University of Vermont will fund research to: 1) define optimal manufacturing, sterilization, and storage conditions for the sealant patch; 2) further evaluate the long-term safety and efficacy of the sealant in animal models...
This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, provides $391,250.00 to Emory University to investigate fibrinogen as a pathologic and targetable mediator of COVID-19-associated coagulopathy. The key objectives are to: 1) Define the impact of therapeutic plasma exchange (TPE) on blood rheology and vascular integrity in COVID-19 patients by analyzing plasma samples before and after...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,319 to Emory University to investigate methods for overcoming refractory cystic fibrosis (CF) defects. The research aims to identify cellular targets that can ameliorate disease by correcting basic defects resulting from premature termination codons (PTCs) in the CF transmembrane conductance regulator (CFTR) gene. Key research activities include...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and test a drug-eluting chest tube to locally manage the pain associated with its use in cardiothoracic surgeries. The $275,752 award supports two key objectives: 1) completing GMP/GLP studies on the drug release kinetics, stability, and manufacturing of the drug-releasing chest tube; and 2) evaluating the mechanical...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...